Table 1.
Patients’ characteristics
| Characteristic | Reduced-dose WBRT | Standard-dose WBRT | p-value |
|---|---|---|---|
| Age at diagnosis (yr) | 58.7 (46.2–75.2) | 56.1 (23.4–75.1) | 0.599 |
| <60 | 11 (55.0) | 44 (64.7) | |
| ≥60 | 9 (45.0) | 24 (35.3) | |
| Sex | 0.852 | ||
| Male | 12 (60.0) | 37 (54.4) | |
| Female | 8 (40.0) | 31 (45.6) | |
| ECOG performance status | 0.683 | ||
| 0–1 | 14 (70.0) | 42 (61.8) | |
| 2–4 | 6 (30.0) | 26 (38.2) | |
| Pathology | 0.399 | ||
| Diffuse large B-cell lymphoma | 17 (85.0) | 64 (94.1) | |
| Other B-cell lymphoma | 1 (5.0) | 1 (1.5) | |
| T-cell lymphoma | 2 (10.0) | 3 (4.4) | |
| Eye involvement | 0.134 | ||
| Yes | 3 (15.0) | 2 (2.9) | |
| No | 17 (85.0) | 66 (97.1) | |
| CSF involvement | 0.703 | ||
| Yes | 3 (15.0) | 6 (8.8) | |
| No | 17 (85.0) | 62 (91.2) | |
| Operation | 0.190 | ||
| Stereotactic biopsy | 20 (100) | 58 (85.3) | |
| Gross total resection | 0 (0.0) | 7 (10.3) | |
| Subtotal resection | 0 (0.0) | 3 (4.4) | |
| Number of lesions | 1.000 | ||
| Single | 5 (25.0) | 19 (27.9) | |
| Multiple | 15 (75.0) | 49 (72.1) | |
| Deep structure involvementa) | 0.864 | ||
| Yes | 14 (70.0) | 44 (64.7) | |
| No | 6 (30.0) | 24 (35.3) | |
| LDH elevation | 0.640b) | ||
| Yes | 6 (30.0) | 27 (39.7) | |
| No | 13 (65.0) | 39 (57.4) | |
| Not reported | 1 (5.0) | 2 (2.9) | |
| Rituximab usage | 0.003 | ||
| Yes | 10 (50.0) | 10 (14.7) | |
| No | 10 (50.0) | 58 (85.3) | |
| Post-radiation cytarabine | 0.003 | ||
| Yes | 12 (60.0) | 15 (22.1) | |
| No | 8 (40.0) | 53 (77.9) |
Values are presented as median (range) or number (%).
WBRT, whole-brain radiotherapy; ECOG, Eastern Cooperative Oncology Group; CFS, cerebrospinal fluid; LDH, lactate dehydrogenase.
a)
Deep structure was defined as basal ganglia, corpus callosum, brainstem, and cerebellum.
b)
Calculated only for reported numbers.